Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

salmeterol

This page shows the latest salmeterol news and features for those working in and with pharma, biotech and healthcare.

AZ rival to GSK’s COPD drug Anoro fails head-to-head test

AZ rival to GSK’s COPD drug Anoro fails head-to-head test

Anoro is one of the drugs GSK is hoping will help replace its COPD blockbuster Seretide/Advair (salmeterol/fluticasone propionate), which has lost patent protection and seen revenues slide in recent

Latest news

  • GSK gets maintenance indication for Trelegy GSK gets maintenance indication for Trelegy

    of patent protection for COPD blockbuster Seretide/Advair (fluticasone propionate/salmeterol), even though competition in the US has been delayed by stringent FDA requirements for low-cost generics that have delayed

  • FDA hands GSK a reprieve by blocking Novartis generic FDA hands GSK a reprieve by blocking Novartis generic

    All three generics have been flummoxed by the complexity of Advair (salmeterol and fluticasone propionate) and the difficulty of showing sufficient equivalence with the Diskus dry powder inhaler used in the ... Teva won approval for its AirDuo product

  • Gilead’s triple HIV drug approval prompts GSK lawsuit Gilead’s triple HIV drug approval prompts GSK lawsuit

    vaccine Shingrix and recently-approved triple therapy for chronic obstructive pulmonary disorder (COPD) Trelegy - as it faces the imminent threat of generic competition to its big-selling respiratory drug Advair (salmeterol

  • AZ’s COPD triple data sets up market clash with GSK AZ’s COPD triple data sets up market clash with GSK

    salmeterol and fluticasone propionate) that was a $7bn product at its peak but has seen sales slip of late, coming in at $3.3bn in the first nine months of 2017.

  • EMA approves GSK’s triple COPD therapy EMA approves GSK’s triple COPD therapy

    GSK has a lot riding on Trelegy as it tries to grow its respiratory business, which has been hit by patent expiries for COPD blockbuster Seretide/Advair (salmeterol and fluticasone propionate) -

More from news
Approximately 1 fully matching, plus 96 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Quick links

Infographics

Multimedia